Hybrigenics Pharma will be present at SOHO 2017, the Annual Meeting of the International Society of Hematologic Oncology, that will take place in Houston, TX, USA from September 13thto 19th.

More than 1,000 attendees and internationally recognized experts will gather to exchange on the latest research progress to better treat leukemia, lymphoma, myeloma, myelodysplastic or proliferative syndromes.

Dr. Jean-François Dufour-Lamartinie, Head of Clinical R&D, will present a poster entitled:

«Phase 2 randomized double-blind placebo-controlled study of inecalcitol combined with decitabine, a new treatment strategy for elderly AML patients unfit for intensive chemotherapy - NCT 028022» which recalls the study protocol and gives an update on the enrollment status. Remi Delansorne, CEO, will also be present to make business development contacts.

Hybrigenics SA published this content on 11 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 September 2017 07:13:11 UTC.

Public permalinkhttp://www.publicnow.com/view/74762EFB99D441CACE5B68A6D9AB070FAAF81867